The aim of this study was to investigate the correlation between cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) tumor markers and different clinicopathological parameters of metastatic breast cancer and the site of distant metastasis. A total of 136 patients with metastatic breast cancer were included and the Radiotherapy and Oncology Database were used to determine their clinical and pathological variables along with the level of CEA and CA 15-3 at the time of diagnosis of distant metastasis. Univariate and multivariate analyses were used to investigate association between clinicopathological parameters, distant metastasis, and tumor marker levels. Increased serum levels of CA 15-3 and CEA at initial diagnosis of metastasis were seen in 59.5% and 44.9% of cases, respectively. Elevation of CA 15-3 and CEA did not correlate with grade, hormonal receptor and HER2 status but increased level of CA 15-3 was associated with tumor nodal status in multivariate analysis, with higher level of CA15-3 associated with more nodal involvement (P<0.001). CEA serum level had a significant correlation with breast cancer's pathological subtypes, with elevated CEA serum level seen more commonly in invasive ductal carcinoma (P= 0.01). Comparing the site of metastasis, the incidence of elevated CA 15-3 and CEA levels were most commonly seen in bone and liver solitary metastasis respectively, however, these differences were not statically significant. In metastatic breast cancer, elevated CA15-3 level was found in majority of cases, while increase in CEA level was seen in less than half of the population. Higher CA 15-3 level represented more frequent nodal involvement. Invasive ductal carcinoma demonstrated elevated CEA level more frequently compared with invasive lobular carcinoma. Tumor marker elevation did not differ regarding the first site(s) of metastasis.
INTRODUCTION
Breast cancer is the most frequently diagnosed cancer among women worldwide, accounting for 25% of all cases. It is the leading cause of cancer death among females 1, 2 . During the past 30 years breast cancer incidence has increased steadily, however; due to screening methods and early detection of breast cancer, the mortality rate of this disease has remained stable 3, 4 . Regional and distant metastasis is a major threat to breast cancer patients, inappropriate prognostic event in the course of disease 5 . The use of tumor markers (TMs) in the management of patients with metastatic breast cancer has been investigated during the past two decades, however; their efficacy remains uncertain [6] [7] [8] . Developing new modalities for specific and targeted localised treatment of different cancers have necessitated the studies on TMs 9, 10 . In breast cancer, the most widely used TMs are cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) 11 . The CA 15-3 (also known as MUC-1) represents sequences of mucins that are overexpressed in malignant cells 12 .
CEA is a protein involved in cell adhesion but its serum level reportedly increases in certain kind of cancers 13 . Although according to the American Society of Clinical Oncology guidelines CEA and Ca 15-3 are not currently recommended as markers for breast cancer screening or early metastasis diagnosis 14 , a number of studies have reported association between TMs elevation and the site of metastasis, prognosis, tumor size and axillary node metastasis 15, 16 . The present study was aimed to retrospectively evaluate the association between these TMs and clinicopathological parameters in metastatic breast cancer and their correlation with the site of distant metastasis.
MATERIALS AND METHODS

Participants
The medical records of 388 patients with metastatic breast cancer treated at the Department of Radiotherapy and Oncology of Ahvaz Golestan Hospital (Iran) between April 2005 and March 2013 were reviewed. Those patients whose TMs were recorded at the time of distant metastasis diagnosis and their complete clinicopathological data were available were included. Excluded cases were 196 cases without any TMs data recording, 41 cases with incomplete record of clinicopathological characteristics, 7 cases with synchronous cancers other than breast cancer, and 8 cases with bilateral breast cancer, respectively. A total of 136 patients were eligible to enter this study. Our institutional politics do not require the patients' approval for reviewing archived medical recording files. However, all private information including patients name and address were kept confidential and were not mentioned in any process of data collecting or analysis in this study.
Clinicopathological Parameters
All clinicopathological parameters including Estrogen Receptor (ER), Progesterone Receptor (PR), human epidermal growth factor receptor 2 (HER2), histopathology of tumor, nodal status, histological grade, and the site of distant metastasis were extracted from the patients' medical 
Tumor Marker Analysis
The laboratory assessments and specific kits were used for the TMs. These assessments used the CA 15-3 and CEA reference ranges as <30 u/ ml and <5ng/ml, respectively.
Data Analysis
The descriptive statistics were used to analyze the data. The frequency and percentage were used for qualification data and mean and 
RESULTS
Data were first analysed with univariate analysis. Those with P-values less than 0.2 were entered in multivariate analysis and processed again. P-values less than 0.05 were considered statistically significant. General characteristics of 136 patients with metastatic breast cancer are Table 2 and Table 3 show respectively the association between the serum level of CA 15-3 and CEA and patients' clinicopathological variables. Elevation of CA 15-3 and CEA did not correlate with grade, hormonal receptor and HER2 status, but increased levels of CA 15-3 were associated with tumor pathological subtypes and nodal status in univariate analysis (P= 0.044 and P <0.001, respectively). However, this correlation was only statistically significant for nodal status in multivariate analysis, with higher level of CA15-3 associated with more frequent nodal involvement (P <0.001).
The CEA serum level at the initial diagnosis of distant metastasis had a significant relation with pathological subtypes of breast cancer in both univariate and multivariate analysis. Comparing invasive ductal and invasive lobular carcinoma, an elevated CEA serum level was more commonly observed in invasive ductal carcinoma (P= 0.01).
In solitary first site metastasis, frequency of elevated and normal CA 15-3 level were almost equal; except for bone metastasis in which elevated CA15-3 serum level was 66% which was twice the normal range (33.9%) ( Table 4) . In multiple metastases, elevated serum level was observed in 58.1% of cases; however, none of these differences were statically significant ( Table 5) . The CEA serum level was merely increased in just over one third of all cases with solitary bone or liver metastasis and multiple first site metastases. However, CEA elevation was observed in about 50% of patients with solitary liver metastasis. It should be mentioned that these differences were not statically significant (P= 0.21) ( Table 6 ).
CONCLUSION
In less developed countries breast cancer is still the most life threatening cancer diagnosed in women; however, in developed countries it has been surpassed by lung cancer to be the second most important cause of cancer deaths in females 2 . Due to heavy burden of breast cancer, numerous studies have been done to find early detectors and predictive factors to guide breast cancer management. In addition to traditional parameters, the use of TMs in breast cancer diagnosis and monitoring has recently spotlighted 15 .
Several studies have reported association between CEA and CA 15-3 and metastatic breast cancer. Yerushalmi et al.,. and Molina et al.,. reported that CA 15-3 level in metastatic breast cancer is higher than CEA 17, 18 . In line with previous studies our findings showed elevated serum levels of CA 15-3 and CEA in 59.5% and 44.9% of all patients, respectively.
A number of studies such as Geng et al.,. and Yerushalmi et al.,. stated an association between different molecular subtypes of breast cancer and CEA and CA15-3 serum levels 11, 17 . In Geng et al.,. a higher percentage of elevated CEA and CA 15-3 were seen in breast cancer luminal subtype. In this study, CA 15-3 was more frequently elevated than CEA in patients with metastatic breast cancer regardless of histopathology of tumor. There was a significant correlation between CEA serum level and histopathology of cancer with increased 21 highest mean values of CA15-3 were observed in patients with liver and multiple metastases with high sensitivity of the CA15-3 test in detecting bone metastases; however, they stated that their observation could not be conclusive due to small group of patients. In our results, CA 15-3 was more frequently elevated than CEA regardless of site(s) of metastasis. While CA 15-3 level did not differ among various site(s) of metastasis -except for bone in which increased level of CA 15-3 were twice as normal -CEA level varied based on site(s) of metastasis. For example, in solitary liver metastasis CEA was more often found to be elevated (52.6%). This percentage was 37.3% and 35.3% in solitary bone and lung metastasis, respectively. When multiple metastases were found at the initial diagnosis of metastasis, 58.1% and 38.7% of cases showed elevated CA 15-3 and CEA serum levels, respectively.
In conclusion, CA 15-3 is more often elevated in metastatic breast cancer than CEA. An elevated serum level of CA 15-3 correlated with more frequent nodal involvement. There was a significant correlation between CEA level and histopathological subtypes of tumor; increased CEA level more frequently found in invasive ductal carcinoma. Although there were some differences in TMs levels regarding initial site(s) of metastasis, none of these findings were statically significant.
